Beckley and atai Leadership Unpack Phase 2b Data, Take Aim at GH’s Dosing Model Post published:July 1, 2025 Post category:Analysis/News/Pα+
Beckley Execs Talk Phase 2b Data, Competition, and Phase 3 Plans Post published:July 1, 2025 Post category:Interviews/Pα+
Beyond the Endpoint: Industry Voices Reflect on Compass’ Phase 3 Readout Post published:June 28, 2025 Post category:Analysis/News/Pα+
Pα+ Psychedelic Bulletin #202: Psychedelics Access ‘Within 12 Months’, RFK Jr. Says; Psychedelics in Washington; Lykos’ New CEO, CMO; New Zealand’s First Psilocybin Prescriber; Judge Recommends Schedule I Placement for DOI and DOC Post published:June 27, 2025 Post category:Psychedelic Bulletin/Pα+
Cautious Optimism, Lingering Questions: Researchers React to Compass’ Phase 3 Psilocybin Results Post published:June 25, 2025 Post category:Analysis/News/Pα+
Australia’s Largest Private Health Insurer Commits $10M to Fund MDMA Therapy for PTSD in First-of-its-Kind Program Post published:June 18, 2025 Post category:Analysis/News/Pα+
Pα+ Psychedelic Bulletin #201: Dispatches from Prague and London; Texas Becomes Leader in Ibogaine Research as Governor Signs $50M Match-Funding Bill; High-Dose LSD Shows Potential in Depression, But Findings Are Fragile Post published:June 13, 2025 Post category:Psychedelic Bulletin/Pα+
May 2025 Psychedelic Patent Update: Gilgamesh Broadens Moat Around Lead Candidate Following Positive Phase 2a Readout; Lykos Publishes Further Continuation Applications; Reconnect Joins Crowded 5-MeO-DMT Patent Landscape Post published:June 12, 2025 Post category:Psychedelic Patent Analysis/Pα+
Breaking: atai Moves to Acquire Beckley, If Phase 2b 5-MeO-DMT Data Delivers Post published:June 2, 2025 Post category:Analysis/News/Pα+
Pα+ Psychedelic Bulletin #199: Lykos Takeover Nears Completion; Fewer than 100 Patients Received Psychedelics in Australia During First 18 Months of Access; Ibogaine Bill Clears Texas Legislature Amid THC Crackdown Post published:May 30, 2025 Post category:Psychedelic Bulletin/Pα+